Epilepsy Drugs Market Share, Size, and Growth Report 2023-2028

IMARC Group, a leading market research company, has recently releases report titled “Epilepsy Drugs Market Share: Global Industry Trends, Size, Growth, Opportunity and Forecast 2023-2028” by IMARC Group, finds that the global epilepsy drugs market size reached US$ 2.16 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.52 Billion by 2028, exhibiting a growth rate (CAGR) of 8.2% during 2023-2028.

What are Epilepsy Drugs?

Epilepsy drugs represent the medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unprovoked, unpredictive, and recurrent episodes of seizures. This condition affects several mental and physical functions causing sudden sensations, loss of awareness, behavioral changes, and severe emotional distress. Epilepsy drug includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as capsules, liquids, tablets, and syrups that are administered through intravenous (IV), oral, and intramuscular routes. These medications are widely used to treat various seizures, including hard-to-treat, mixed, partial onset, tonic-clonic, and acute repetitive. Epilepsy drugs prevent life-threatening adverse effects, are safe, offer better tolerability, and minimize the negative impact on the cognitive functions. As a result, these medications are extensively available across hospitals and pharmacies.

Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/epilepsy-drugs-market/requestsample

Epilepsy Drugs Market Trends and Drivers:

The escalating prevalence of this condition, owing to the increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries, is among the primary factors driving the epilepsy drugs market. Besides this, the elevating requirement for these medications to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments to aid patients in restoring their usual psychosocial and vocational activities is further augmenting the market growth. Moreover, the launch of several policies by the government bodies to educate the masses about epilepsy, promote research, and provide active support by expediting more suitable treatment options is also catalyzing the global market. Apart from this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another significant growth-inducing factor. Furthermore, the development of extended-release (ER) medicine formulations that allow longer dosing intervals while minimizing the fluctuations in serum medication levels to improve efficacy and adherence is anticipated to propel the epilepsy drugs market over the forecasted period.

Ask Analyst for Customization and Explore Full Report with TOC List of Figure: https://www.imarcgroup.com/epilepsy-drugs-market

Epilepsy Drugs Market 2023-2028 Analysis and Segmentation: The report has segmented the market on the basis of

Generation Type Insights

• First Generation Drugs

  • Phenytoin

  • Carbamazepine

  • Oxcarbazepine

  • Valproate

  • Ethosuximide

  • Primidone

  • Phenobarbital

• Second Generation Drugs

  • Levetiracetam

  • Lamotrigine

  • Topiramate

  • Pregabalin

  • Rufinamide

  • Zonisamide

• Third Generation Drugs

  • Lacosamide

  • Perampanel

  • Eslicarbazepine Acetate

  • Ezogabine/Retigabine

The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.

Anti-Epileptics Drugs Type Insights

• Narrow-Spectrum AEDs

• Broad-Spectrum AEDs

A detailed breakup and analysis of the epilepsy drugs market based on the anti-epileptics drugs type has also been provided in the report. This includes narrow and broad-spectrum AEDs. According to the report, broad-spectrum AEDs accounted for the largest market share.

Distribution Channel Insights

• Hospital Pharmacy

• Pharmacy Stores

• Others

A detailed breakup and analysis of the epilepsy drugs market based on the distribution channel has been provided in the report. This includes hospital pharmacy, pharmacy stores, and others. According to the report, hospital pharmacy accounted for the largest market share. Breakup by Region:

• North America: (United States, Canada)

• Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)

• Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• Latin America: (Brazil, Mexico, Others)

• Middle East and Africa

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc.

Contact Us:

IMARC Services Private Limited. 30 N Gould St Ste R Sheridan, WY 82801 USA – Wyoming Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.